Annual report pursuant to Section 13 and 15(d)

Licenses Acquired - Additional Information (Detail)

v3.3.1.900
Licenses Acquired - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Oct. 31, 2015
Sep. 30, 2015
Jul. 16, 2015
May. 31, 2015
Apr. 28, 2015
Apr. 02, 2015
Feb. 28, 2015
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Feb. 17, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments to Acquire Intangible Assets               $ 1,250,000 $ 0 $ 0  
Research And Development In Process               11,408,000 0 0  
Stock Issued During Period, Value, Issued for Services               1,000 4,000 4,000  
Research And Development Expense               18,402,000 10,239,000 25,682,000  
Payments to Acquire in Process Research and Development               $ 200,000      
Share Price               $ 2.93      
Stock Issued During Period, Value, Other                 3,502,000    
General And Administrative Expense               $ 21,584,000 10,413,000 $ 10,098,000  
NeuPharma [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Research And Development In Process               1,000,000      
National Institutes of Health [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payment of Upfront Milestone Fees     $ 700,000                
New Zealand Pharmaceuticals Ltd [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Reimbursement Revenue     600,000                
Dana-Farber [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Shares Issued, Price Per Share   $ 4.39   $ 0.065              
Stock Issued During Period, Shares, Issued for Services   136,803   500,000              
Stock Issued During Period, Value, Issued for Services   $ 600,000   $ 32,500              
Escala Therapeutics, Inc [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payment of Upfront Fees     $ 1,300,000                
Reimbursement Revenue               $ 1,300,000      
UCLB [Member] | Minimum [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Royalty Percentage               3.00%      
UCLB [Member] | Maximum [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Royalty Percentage               5.00%      
Collaboration Agreement with TGTX [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments for Fees               $ 500,000      
Collaboration Agreement with TGTX [Member] | NeuPharma [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments for Fees               25,000      
Collaboration Agreement with TGTX [Member] | TG Therapeutics, Inc [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments for Fees               600,000 $ 0    
Agreement With City Of Hope [Member] | Mustang Bio, Inc [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments to Acquire in Process Research and Development               $ 2,000,000      
Chief Executive Officer [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Stock Issued During Period, Shares, Issued for Services               1,000,000      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights               50% in four annual equal tranches of 12.5%, with the remaining 50% vesting upon the achievement of certain performance goals.      
Coronado SO Co, Inc [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Research And Development In Process               $ 1,607,000      
Payments for Fees             $ 900,000        
Stock Issued During Period, Shares, Other             150,000        
Research And Development Expense $ 500,000                    
Checkpoint Therapeutics, Inc [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Research And Development In Process               3,159,000      
Stock Issued During Period, Value, Purchase of Assets               22,000,000      
Checkpoint Therapeutics, Inc [Member] | Dana-Farber [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Stock Issued During Period, Value, Purchase of Assets               11,400,000      
Helocyte Biosciences Inc [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Research And Development Expense               200,000      
Licensing Agreements [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments to Acquire Intangible Assets         $ 50,000 $ 150,000          
Research And Development In Process               147,000      
Intangible Assets, Net (Excluding Goodwill), Total               500,000      
Licensing Agreements [Member] | City Of Hope [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments for Fees               $ 2,000,000      
Stock Issued During Period, Shares, Other               1,000,000      
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent               30.00%      
Share Price               $ 0.147      
Stock Issued During Period, Value, Other               $ 100,000      
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued           500,000          
Licensing Agreements [Member] | Dana-Farber [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments for Fees               $ 1,000,000      
Licensing Agreements [Member] | Coronado SO [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Marketability Percentage Of Invested Capital               44.80%      
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent               30.00%      
Share Price               $ 1.19      
Licensing Agreements [Member] | IV Tramadol [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Payments to Acquire Intangible Assets               $ 1,000,000      
Payments for Fees             $ 2,000,000        
Avenue Therapeutics, Inc. [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Shares Issued, Price Per Share               $ 0.146      
Research And Development Expense               $ 21,000      
Debt Instrument, Fee Amount                     $ 3,000,000
General And Administrative Expense               $ 29,000      
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Stock Issued During Period, Shares, Issued for Services               1,000,000      
Avenue Therapeutics, Inc. [Member] | Consultants [Member]                      
Research and Development Arrangement, Contract to Perform for Others [Line Items]                      
Stock Issued During Period, Shares, Issued for Services               150,000      
Research And Development Expense               $ 21,000